Scientists have developed a potential game-changer in heart disease prevention: a one-time gene-editing injection that slashes cholesterol levels by up to 69%. This breakthrough treatment, named VERVE-102, targets the PCSK9 gene in the liver, which is responsible for regulating LDL (“bad”) cholesterol. Unlike daily statins, which only manage cholesterol, this therapy could permanently lower it with a single dose—revolutionizing how we approach cardiovascular care.
Early human trials in the UK have already shown promising results. By silencing the PCSK9 gene, the body naturally clears harmful cholesterol from the bloodstream far more efficiently. Experts believe that if further trials confirm its safety and effectiveness, VERVE-102 could drastically reduce the risk of heart attacks and eliminate the lifelong dependency on cholesterol medications for millions around the world.
#CholesterolBreakthrough #GeneEditing #HeartHealth #MedicalInnovation #VERVE102Scientists have developed a potential game-changer in heart disease prevention: a one-time gene-editing injection that slashes cholesterol levels by up to 69%. This breakthrough treatment, named VERVE-102, targets the PCSK9 gene in the liver, which is responsible for regulating LDL (“bad”) cholesterol. Unlike daily statins, which only manage cholesterol, this therapy could permanently lower it with a single dose—revolutionizing how we approach cardiovascular care.
Early human trials in the UK have already shown promising results. By silencing the PCSK9 gene, the body naturally clears harmful cholesterol from the bloodstream far more efficiently. Experts believe that if further trials confirm its safety and effectiveness, VERVE-102 could drastically reduce the risk of heart attacks and eliminate the lifelong dependency on cholesterol medications for millions around the world.
#CholesterolBreakthrough #GeneEditing #HeartHealth #MedicalInnovation #VERVE102
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Greek
Arabic